Four immunoassays offer 14 in vitro tumor markers

Los Angeles-Diagnostic Products Corp., has been granted FDA approval to market four PSA immunoassays for prostate cancer detection: Immulite PSA, Immulite 2000 PSA, Immulite Third Generation PSA, and Immulite 2000 Third Generation PSA. The assays are intended for in vitro diagnostic use with the Immulite and Immulite 2000 immunoassay analyzers.